Polyrizon Ltd. (PLRZ)

$1.55 -0.09 (-5.49%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,429,814
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorp...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 374 0120
Address:
5 Ha-Tidhar Street, Ra'anana, Israel
Swats20
Swats20 Mar. 11 at 4:50 PM
$PLRZ come on!! 🚀🚀
0 · Reply
DARKP00L
DARKP00L Mar. 10 at 12:25 PM
$PLRZ 07:57 on Mar. 10 2026 Polyrizon Announces Production Of Good Manufacturing Practice Batch Of Clinical Trial Material For Its Lead Product Candidate #tradeideas
0 · Reply
StockNews_Live
StockNews_Live Mar. 10 at 11:56 AM
$PLRZ 🎯 STOCK NEWS ALERT 💵 Price: $12.81 (-0.99%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Polyrizon Ltd. announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate. This milestone follows the Company’s… 📎 https://stocknews.live/news/PLRZ/polyrizon-announces-gmp-manufacturing-13741.html
0 · Reply
raulaa
raulaa Mar. 5 at 8:36 PM
$PLRZ whats happening here?
0 · Reply
LORDG00N
LORDG00N Mar. 5 at 8:23 PM
$PLRZ nice
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 9:44 PM
$PLRZ Current Stock Price: $13.40
0 · Reply
Jacekons23
Jacekons23 Mar. 3 at 10:10 PM
$PLRZ I’m at $1,200/share for some odd reason…hmm I wonder why. Been holding for a fat minute. I’m gonna stay away from this and never sell. My money is worth $12😂 
0 · Reply
LORDG00N
LORDG00N Mar. 3 at 7:16 PM
$PLRZ the war surely not helping
0 · Reply
LORDG00N
LORDG00N Mar. 3 at 7:15 PM
$PLRZ man that sucks
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 10:32 PM
$PLRZ RSI: 44.30, MACD: -0.0101 Vol: 0.83, MA20: 13.59, MA50: 12.78 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on PLRZ
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Mar 10, 2026, 7:55 AM EDT - 6 days ago

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Feb 26, 2026, 8:12 AM EST - 17 days ago

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Feb 17, 2026, 11:32 AM EST - 26 days ago

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Feb 10, 2026, 6:55 AM EST - 4 weeks ago

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Feb 6, 2026, 7:55 AM EST - 5 weeks ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Feb 4, 2026, 7:12 AM EST - 5 weeks ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Jan 22, 2026, 9:25 AM EST - 7 weeks ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Jan 13, 2026, 8:39 AM EST - 2 months ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Jan 8, 2026, 8:45 AM EST - 2 months ago

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Jan 5, 2026, 9:07 AM EST - 2 months ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Jan 2, 2026, 8:30 AM EST - 2 months ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Dec 29, 2025, 7:20 AM EST - 2 months ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Dec 19, 2025, 8:20 AM EST - 3 months ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Dec 11, 2025, 8:15 AM EST - 3 months ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Dec 8, 2025, 8:55 AM EST - 3 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 4, 2025, 7:32 AM EST - 3 months ago

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 3, 2025, 9:28 AM EST - 3 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Dec 2, 2025, 7:55 AM EST - 3 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Nov 6, 2025, 8:55 AM EST - 4 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Oct 6, 2025, 8:21 AM EDT - 5 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 19, 2025, 8:15 AM EDT - 6 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Sep 12, 2025, 7:26 AM EDT - 6 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2025, 8:14 AM EDT - 7 months ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jul 15, 2025, 7:55 AM EDT - 8 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Jun 12, 2025, 7:32 AM EDT - 9 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 23, 2025, 4:15 PM EDT - 10 months ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 21, 2025, 7:10 AM EDT - 10 months ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025, 7:45 AM EDT - 10 months ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 25, 2025, 7:37 AM EDT - 11 months ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 11, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Apr 1, 2025, 4:09 PM EDT - 1 year ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 1 year ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 27, 2025, 8:25 AM EDT - 1 year ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 25, 2025, 4:04 PM EDT - 1 year ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Mar 14, 2025, 8:35 AM EDT - 1 year ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 13, 2025, 7:51 AM EDT - 1 year ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 11, 2025, 4:27 PM EDT - 1 year ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Mar 10, 2025, 7:47 AM EDT - 1 year ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Jan 30, 2025, 5:55 AM EST - 1 year ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Jan 23, 2025, 6:40 AM EST - 1 year ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Dec 30, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Dec 19, 2024, 7:22 AM EST - 1 year ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Dec 18, 2024, 6:25 AM EST - 1 year ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Dec 13, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Dec 2, 2024, 8:02 AM EST - 1 year ago

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Oct 30, 2024, 1:50 PM EDT - 1 year ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Oct 30, 2024, 10:28 AM EDT - 1 year ago

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

Oct 28, 2024, 7:02 PM EDT - 1 year ago

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

Swats20
Swats20 Mar. 11 at 4:50 PM
$PLRZ come on!! 🚀🚀
0 · Reply
DARKP00L
DARKP00L Mar. 10 at 12:25 PM
$PLRZ 07:57 on Mar. 10 2026 Polyrizon Announces Production Of Good Manufacturing Practice Batch Of Clinical Trial Material For Its Lead Product Candidate #tradeideas
0 · Reply
StockNews_Live
StockNews_Live Mar. 10 at 11:56 AM
$PLRZ 🎯 STOCK NEWS ALERT 💵 Price: $12.81 (-0.99%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Polyrizon Ltd. announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate. This milestone follows the Company’s… 📎 https://stocknews.live/news/PLRZ/polyrizon-announces-gmp-manufacturing-13741.html
0 · Reply
raulaa
raulaa Mar. 5 at 8:36 PM
$PLRZ whats happening here?
0 · Reply
LORDG00N
LORDG00N Mar. 5 at 8:23 PM
$PLRZ nice
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 9:44 PM
$PLRZ Current Stock Price: $13.40
0 · Reply
Jacekons23
Jacekons23 Mar. 3 at 10:10 PM
$PLRZ I’m at $1,200/share for some odd reason…hmm I wonder why. Been holding for a fat minute. I’m gonna stay away from this and never sell. My money is worth $12😂 
0 · Reply
LORDG00N
LORDG00N Mar. 3 at 7:16 PM
$PLRZ the war surely not helping
0 · Reply
LORDG00N
LORDG00N Mar. 3 at 7:15 PM
$PLRZ man that sucks
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 10:32 PM
$PLRZ RSI: 44.30, MACD: -0.0101 Vol: 0.83, MA20: 13.59, MA50: 12.78 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Swats20
Swats20 Mar. 2 at 4:17 PM
$PLRZ let’s move 🚀
1 · Reply
Stock_Catcher
Stock_Catcher Feb. 27 at 2:18 AM
Fortune Friday Watchlist Pt. 4 $IXHL $OPEN $PLRZ $VCIG $SVRE Let's Do Great Tomorrow
0 · Reply
raulaa
raulaa Feb. 26 at 3:32 PM
$PLRZ it seems to have no eftect so far
0 · Reply
Swats20
Swats20 Feb. 26 at 2:56 PM
$PLRZ
0 · Reply
raulaa
raulaa Feb. 26 at 1:59 PM
$PLRZ
0 · Reply
Stock_Catcher
Stock_Catcher Feb. 26 at 1:12 PM
$PLRZ Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
0 · Reply
raulaa
raulaa Feb. 26 at 11:25 AM
$PLRZ zzzz
0 · Reply
fivehundredpercent
fivehundredpercent Feb. 24 at 5:06 PM
$PLRZ break out over this 16 level there is a gap close to 40 chart
0 · Reply
Swats20
Swats20 Feb. 19 at 6:22 PM
$PLRZ waiting for some catalyst..
0 · Reply
LORDG00N
LORDG00N Feb. 19 at 3:46 PM
$PLRZ on their last press release, they said they will begin the clinical test at the end of 2025- early 2026 so we should receive some news in like 4-6 weeks
0 · Reply
6GodEnergy
6GodEnergy Feb. 17 at 3:48 PM
- $BLMZ $PLRZ $BTCT $BTOG [*]
0 · Reply
Tbirdyguy
Tbirdyguy Feb. 17 at 2:37 PM
$PLRZ wtf is some actual news? They have PRd the aviation aqcuisition 3 times, stalling, then followed by nothing again today. Def need news
0 · Reply